Relation of lower hematocrit to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure (from the Studies of Left Ventricular Dysfunction Prevention trial)

Sandeep R Das; Daniel L Dries; Mark H Drazner; Clyde W Yancy; Claudia U Chae

doi:10.1016/j.amjcard.2005.05.030

Relation of lower hematocrit to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure (from the Studies of Left Ventricular Dysfunction Prevention trial)

Am J Cardiol. 2005 Sep 15;96(6):827-31. doi: 10.1016/j.amjcard.2005.05.030.

Authors

Sandeep R Das¹, Daniel L Dries, Mark H Drazner, Clyde W Yancy, Claudia U Chae

Affiliation

¹ Donald W. Reynolds Cardiovascular Clinical Research Center, Dallas, Texas, USA. sandeep.das@utsouthwestern.edu

PMID: 16169371
DOI: 10.1016/j.amjcard.2005.05.030

Abstract

The relation between hematocrit and progression from asymptomatic left ventricular (LV) systolic dysfunction to symptomatic heart failure (HF) was examined in 2,821 patients from the Studies of Left Ventricular Dysfunction Prevention trial. Patients in the lowest hematocrit quartile (hematocrit < or = 40%) were at increased risk for the development of HF symptoms (hazard ratio [HR] 1.79, 95% confidence interval [CI] 1.37 to 2.34), first HF hospitalization (HR 2.35, 95% CI 1.52 to 3.62), and death or the development of HF symptoms (HR 1.60, 95% CI 1.28 to 1.99) compared with patients in the highest hematocrit quartile (hematocrit > 46%).

Publication types

Comparative Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Aged
Anemia / blood
Anemia / complications*
Female
Heart Failure / blood*
Hematocrit*
Humans
Incidence
Male
Middle Aged
Risk Factors
Ventricular Dysfunction, Left / blood*

Abstract

Publication types

MeSH terms

Grants and funding